Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.
about
Recent advances of novel targeted therapy in non-small cell lung cancerAssociation of cetuximab with adverse pulmonary events in cancer patients: a comprehensive reviewAnaphylactic reactions to oligosaccharides in red meat: a syndrome in evolution.Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancerActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximabEGFR targeted therapy in non-small cell lung cancer: potential role of cetuximabTargeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancerEpidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidenceOncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancerPhase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma.Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor.Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis.Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data.Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck.A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.Lung cancer. 9: Molecular biology of lung cancer: clinical implications.Development of inhibitors for protein tyrosine kinases.Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinomaSTAT proteins: novel molecular targets for cancer drug discovery.Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors.EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.New trends in epidermal growth factor receptor-directed monoclonal antibodies.The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancerThe advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer.Clinical impact of novel treatment strategies.Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy.Epidermal growth factor receptor and bladder cancer.Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibromaControversies and challenging therapeutic modalities in gastric cancer.Therapeutic IMC-C225 antibody inhibits breast cancer cell invasiveness via Vav2-dependent activation of RhoA GTPasePhase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.Therapeutic potential of tyrosine kinase inhibitors in breast cancer.A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.
P2860
Q21092930-6DD49D6D-F594-4D44-A5B9-CEEC4DE779C6Q21198850-C5BAB5DD-FF76-4DA8-BBAD-CD0AC6655FB1Q21245667-D66AEC52-D8A3-429E-A7ED-5105841B3BACQ24187972-0D3A7C5B-53C6-444E-84F5-7A3701748ADEQ24600031-FB07E517-6D53-4774-A79C-C92FAD0213B0Q24652337-0387C77B-2488-4CAD-8A95-3087E244C8C4Q26765429-F28366AA-0517-46C1-84BD-932EA8E5B249Q26771952-5F1B9A5E-3800-47D7-93FC-7105C8AD5226Q27853131-5376B969-9E2F-4081-9F58-BA11686B9F97Q28071772-B5A5CFE4-EB78-4E47-8E8F-EDAB978165E0Q28077545-A2F98D33-6A09-49E9-8E73-7ED7DD63AD65Q33162775-566F4EE5-5D2C-400B-8ABC-DA1A073AF063Q33186341-4E248C1D-8854-4C23-9E7D-329CA3978F43Q33622614-0D5FF940-21E6-42F3-BC5E-A552354AFF39Q33644407-9A819C5C-E0B3-4797-9E8F-BA3A0D83D936Q33873118-C7F27ED6-19DC-42A4-A88B-ABC21C507B9DQ33916035-7F0AC6CF-D55F-435B-A707-11E035D20B4BQ33931775-BFECA73F-00DA-4B5D-949A-92EF6A4D4DB1Q33972805-2CB44CED-AC9B-403C-881F-8F9F32B091A7Q34103669-112BF551-EBCE-40C9-A085-C5330877A265Q34158993-585603C3-23DD-4D64-9F2E-40E781E95B7CQ34293579-F4A85C7E-230D-447F-BBF6-69DAECDB3944Q34570074-30501A93-D53C-46BE-B8D2-734AFD6AB06CQ34618994-031081E1-C8BE-4BD9-A254-B25A22DC0EFFQ34621577-C611035A-2F74-476C-B800-93E5172923D8Q34622547-84F16EC5-87F6-4486-8AF7-AA68F24B069BQ34648886-0FA3DF7F-2939-4A08-815A-104ACAA6AF95Q34936052-830915C5-B35F-4248-BB4B-DC81AB2DC036Q34973413-89143540-4822-4B1A-8B36-2784654C5178Q34988074-B04C0094-8E23-4BE8-82D7-A17AAADF32D3Q35023433-FE5CAA0C-2E52-48F7-B77C-C127D5CEACF0Q35088274-33BB1F51-FDE3-4AB7-BFC6-80944E061092Q35129981-50B064F2-E9A5-40BC-BF79-855F757FD39BQ35151696-9E8B3D8C-6406-431B-97F6-0C9D814B5CF3Q35154219-36C938F1-6CB4-4EB6-A278-1B40FF9C97B3Q35469548-2A7032AD-F1FA-4E74-B563-8C6315B8B909Q35583019-83885890-6C32-4090-8684-DDD3CA1126AEQ35584416-1C8D7F1F-6CFB-443F-8092-6FC4D58AA57FQ35589209-24B0A0E6-61E4-4EC4-8451-656BB30A74E6Q35597532-3BCEE604-C21F-4D4B-9EED-7C2A680DF243
P2860
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Phase I studies of anti-epider ...... in combination with cisplatin.
@ast
Phase I studies of anti-epider ...... in combination with cisplatin.
@en
Phase I studies of anti-epider ...... in combination with cisplatin.
@nl
type
label
Phase I studies of anti-epider ...... in combination with cisplatin.
@ast
Phase I studies of anti-epider ...... in combination with cisplatin.
@en
Phase I studies of anti-epider ...... in combination with cisplatin.
@nl
prefLabel
Phase I studies of anti-epider ...... in combination with cisplatin.
@ast
Phase I studies of anti-epider ...... in combination with cisplatin.
@en
Phase I studies of anti-epider ...... in combination with cisplatin.
@nl
P2093
P1476
Phase I studies of anti-epider ...... in combination with cisplatin
@en
P2093
B Burtness
J Mendelsohn
M R Cooper
P304
P356
10.1200/JCO.2000.18.4.904
P407
P577
2000-02-01T00:00:00Z